Vogenx, Inc. (VOGX) IPO

How this Dossier is built

A Bellipo Dossier is built from the filing itself. We aggregate the company's S-1 and its amendments, extract the disclosures that move a deal, and compile them into a single structured brief — the financial statements normalized into comparable lines, the use-of-proceeds split between primary and secondary, the capitalization and ownership table, the underwriting syndicate, insider selling, the auditor and its prior engagements, and the ranked risk factors. Every figure is traced to the source filing rather than the press release. The result is a desk-grade read of what the company disclosed, not what it announced — in plain English, in about five minutes.

Company Information

Vogenx is a clinical-stage biopharmaceutical company developing a treatment for post-bariatric hypoglycemia, the dangerous drops in blood sugar that can follow weight-loss surgery. Its lead candidate, mizagliflozin, is an orally administered, minimally absorbed selective SGLT1 inhibitor (a drug that blocks glucose absorption in the gut) in development for that indication and also for gastroparesis, a condition in which the stomach empties too slowly, and for GIP-dependent Cushing's syndrome, a rare hormonal disorder. The filing states mizagliflozin was discovered by Kissei Pharmaceutical and that Vogenx obtained exclusive rights in 2021 on a worldwide basis excluding Japan, Korea and Taiwan, against milestones and royalties. The company is based in Raleigh, North Carolina and incorporated in Delaware, and has no approved product and no revenue. Everything in this dossier is read from the filing.

Lead program as filed

The arc

1. No expected pricing date appears in the filing or on exchange calendars as of this draft. The listing is dateless.
2. The auditor's report contains both a going-concern explanatory paragraph and an explanatory paragraph relating to a restatement of the financial statements.
3. Cash and cash equivalents were $251 thousand at March 31, 2026, against a deal size of $75.0 million at the midpoint. Our own comparison, from filed figures.

Form S-1/A, accession 0001185185-26-003162 (filed 2026-07-29).

The Bellipo Take

The smallest deal of the week, one clinical candidate, one bank, $251 thousand of cash and an audit report carrying both a going-concern paragraph and a restatement. Everything here rests on the offering closing.

1. Two completed Phase 2 studies in post-bariatric hypoglycemia are disclosed, in which the company states statistically significant reductions in postprandial glucose absorption and insulin secretion were observed.
2. The filing states mizagliflozin has been administered to over 500 subjects across 10 clinical studies.
3. Estimated net proceeds of approximately $67.8 million at the midpoint against a stated runway through 2028.
4. Operating losses are small in absolute terms - a $475 thousand net loss in Q1 2026 and a $11.3 million accumulated deficit.
5. The offering is on a firm-commitment basis, not best efforts.

1. Cash and cash equivalents of $251 thousand at March 31, 2026. Without this offering there is no funded plan.
2. The auditor report carries both a going-concern explanatory paragraph and a restatement.
3. One bank runs the book. The other four biotech deals this week carry three to seven.
4. The clinical base for the lead indication is 24 PBH patients across two studies.
5. The Phase 3 is planned for 2027 subject to additional funding - the company's own qualifier, on top of this raise.
6. Three different post-offering share counts appear in the same document and none of them reconcile.
7. No expected pricing date is disclosed, so we cannot schedule the deal.

The line

No approval decision is pending on this deal and there is no PDUFA date. The next disclosed step is patient screening for the EMERGE study, beginning in 2026.

All figures read from Form S-1/A, accession 0001185185-26-003162 (filed 2026-07-29). We do not handicap regulatory outcomes.

Related IPO dossiers